14 Overstated
Studies comparing premenopausal and perimenopausal women show circulating LPS levels are significantly higher in perimenopause.
"In fact, there are studies that look at women in premenopause versus women in perimenopause, and the the amount of circulating LPS is dramatically higher, right?" (said at 0:02:49)
While longitudinal research across the menopausal transition shows evidence of increased gut barrier permeability and microbial translocation, the claim that circulating lipopolysaccharide (LPS) is "dramatically higher" in perimenopausal compared to premenopausal women is overstated. In a longitudinal cohort from the Study of Women's Health Across the Nation (SWAN; n = 65), surrogate markers of microbial translocation and gut permeability increased modestly across the menopause transition (from pre- to postmenopause): LPS-binding protein (LBP) increased by 3.7% (P = 0.05), soluble CD14 (sCD14) by 8.9% (P = 0.0002), and fatty acid binding protein 2 (FABP2) by 22.8% (P = 0.001). Direct measurements of circulating LPS do not show dramatic spikes between premenopause and perimenopause.
- partial: Gut permeability, inflammation, and bone density across the menopause transition. (JCI insight 2020) · cited 93x in the literature
"In our primary analysis, FABP2, LBP, and sCD14 increased by 22.8% (P = 0.001), 3.7% (P = 0.05), and 8.9% (P = 0.0002), respectively, from pre- to postmenopause." (abstract, results, passage verified)
pubmedfull study (doi)
A reduction in gut Lactobacilli and Bifidobacteria species is associated with increased weight and a reduction in basal metabolic rate.
"We also tend to see a reduction in lactobacilli uh and bifidobacteria species as well, which both of those reductions then have a weight effect as well because uh reduction in lacto and bifido is associated with an increase in weight and a and a reduction of basal metabolic rate in people." (said at 0:04:30)
While lower relative abundances of Bifidobacterium species (and certain Lactobacillus species) are frequently observed in individuals with obesity compared to lean individuals, and their metabolites (such as short-chain fatty acids) are involved in host metabolic regulation and thermogenesis in preclinical models, the assertion that a reduction in these bacteria is directly associated with or causes a reduction in basal metabolic rate in humans is overstated. Clinical research directly evaluating resting energy expenditure in relation to gut microbiota composition remains very limited and preliminary, with only recent small trials beginning to explore whether specific probiotic strains can influence resting energy expenditure.
- partial: Effect of Intake of Bifidobacteria and Dietary Fiber on Resting Energy Expenditure: A Rand… (Nutrients 2024) · cited 10x in the literature
"At week 4, the REE score of the GCL2505 and inulin group was significantly higher than that of the placebo group, with a difference of 84.4 kcal/day. In addition, fecal bifidobacteria counts were significantly increased in the GCL2505 and inulin group. Our results indicated that the intake of GCL2505 and inulin improves energy balance, which is known to be a major factor of obesity, by modulating the microbiota in the gut. This is the first report to demonstrate the effects of probiotics and dietary fiber on REE in humans." (abstract, results, passage verified)
pubmedfull study (doi) - context: Unraveling the gut microbiota's role in obesity: key metabolites, microbial species, and t… (Journal of bacteriology 2025) · cited 45x in the literature
"Conversely, beneficial bacteria like Akkermansia muciniphila , Lactobacillus spp., and Bifidobacterium spp. enhance gut barrier integrity, regulate SCFA production, and modulate fasting-induced adipose factor, which collectively support metabolic health by reducing fat storage and inflammation. Metabolites such as SCFAs (acetate, propionate, and butyrate) interact with G-protein coupled receptors to regulate lipid metabolism and promote the browning of white adipose tissue (WAT), thus enhancing thermogenesis and energy expenditure." (abstract, passage verified)
pubmedfull study (doi)
Women entering perimenopause experience a significant increase in systemic inflammatory markers including hs-CRP, IL-6, and TNF-alpha.
"so, when you look at systemic inflammation in women entering perimenopause, you see a significant rise in things like hs-CRP, which is a global inflammatory marker, interleukin-6, TNF-alpha." (said at 0:04:50)
While longitudinal cohort studies observe elevations in certain inflammatory markers across the menopausal transition, asserting a uniform, significant rise across hs-CRP, IL-6, and TNF-alpha upon entering perimenopause overstates the findings. In the longitudinal Penn Ovarian Aging Study (PMID: 34589780), log IL-6 levels were significantly higher in late perimenopause compared to premenopause, but increases were nuanced, showed significant interactions with early life adversity, and did not demonstrate a uniform baseline rise across hs-CRP and TNF-alpha. Furthermore, prospective studies examining the menopausal transition (such as PMID: 19126626) demonstrate that changes in systemic inflammatory markers like CRP are strongly mediated by concomitant increases in visceral adiposity rather than being an isolated universal cytokine surge across all these markers.
- context: Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prosp… (The Journal of clinical endocrinology and metabolism 2009) · cited 278x in the literature
"The increase in intraabdominal fat was correlated positively with the change in SAA (r = 0.31, P = 0.02), CRP (r = 0.56, P < 0.001), tPA (r = 0.40, P = 0.002), and leptin (r = 0.41, P = 0.002)... After adjustment for change in sc abdominal fat, the correlation between change in CRP, tPA, leptin, and adiponectin remained significantly associated with change in intraabdominal fat." (abstract, results)
pubmedfull study (doi) - context: Influences of the menopause transition and adverse childhood experiences on peripheral bas… (Brain, behavior, & immunity - health 2021) · cited 17x in the literature
"Log IL-6 levels were higher in the late perimenopause versus premenopause (p = 0.035). Menopause stage × ACE interaction was observed for log IL-6, IL-1β, and TNF-α (p = 0.042, p = 0.054, p = 0.053, respectively); for individuals with high (≥2) ACE exposure, IL-6 was higher in the late perimenopause (p = 0.015) while IL-1β and TNF-α were lower in the postmenopause versus premenopause (p = 0.019 and p = 0.020)." (abstract, results)
pubmedfull study (doi)
Lipopolysaccharide (LPS) can cross the blood-brain barrier and activate microglial immune cells, inducing brain inflammation.
"It can enter into almost any tissue, including crossing the blood-brain barrier. So, it does a good job of doing that. When it does cross the blood-brain barrier, it does induce inflammation in the brain. It activates something called microglial cells, which are the immune cells in the brain and central nervous system." (said at 0:11:40)
While lipopolysaccharide (LPS) activates microglial cells and induces neuroinflammation, the speaker's claim that LPS 'does a good job' of crossing the blood-brain barrier (BBB) is overstated. Quantitative pharmacokinetic studies in animal models (such as Banks et al., 2010) show that intact LPS penetrates the BBB only minimally (roughly 0.025% of an intravenous dose enters the CNS). Instead of freely penetrating the brain, circulating LPS primarily triggers neuroinflammation by acting on endothelial cells of the BBB, circumventricular organs, vagal afferents, or by disrupting BBB integrity and promoting peripheral cytokine signaling.
- contradicts: Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. (Brain, behavior, and immunity 2010) · cited 362x in the literature
"Brain endothelia also sequestered small amounts of I-LPS and about 0.025% of an intravenously injected dose of I-LPS crossed the BBB to enter the CNS... In conclusion, brain uptake of circulating I-LPS is so low that most effects of peripherally administered LPS are likely mediated through LPS receptors located outside the BBB." (abstract, results)
pubmedfull study (doi) - supports: LPS-Induced Neuroinflammation in Neurodegenerative Diseases: A Double-Edged Sword? (Molecular neurobiology 2026) · cited 1x in the literature
"Lipopolysaccharide (LPS), a glycolipid endotoxin derived from Gram-negative bacteria, activates Toll-like receptor 4 (TLR4) signaling in microglia and astrocytes, initiating neuroimmune cascades characterized by pro-inflammatory cytokine release, oxidative stress, and glial reactivity." (abstract, results, passage verified)
pubmedfull study (doi)
Lipopolysaccharide (LPS) interferes with serotonin and dopamine binding in the brain.
"LPS also interferes with serotonin and dopamine binding in the brain, which means that your happy hormone and your hormone that drives motivation and reward centers, that's not working very well." (said at 0:12:21)
The claim overstates preclinical animal findings. In rodent models, systemic administration of lipopolysaccharide (LPS) causes neuroinflammation that alters monoaminergic receptor binding in specific brain regions, but these changes are receptor- and region-specific (for instance, decreasing 5-HT1A binding in the hippocampus while increasing dopamine D2 receptor binding in the nucleus accumbens, with no effect on D1 or 5-HT2A receptors). Generalizing these complex, region-specific rodent changes to a blanket assertion that LPS straightforwardly disrupts serotonin and dopamine receptor binding and function in humans is unsupported by direct clinical evidence.
The American Diabetes Association published a paper stating that the primary insult starting insulin resistance is endotoxins (LPS).
"even they published almost now nine years ago that the primary insult, and this is this is quoted from a paper published by the American Diabetes Association, the primary insult that starts the process of insulin resistance is the presence of endotoxins, which is the LPS." (said at 0:16:20)
A landmark 2007 study published in the journal Diabetes (an official journal of the American Diabetes Association) by Cani et al. demonstrated that continuous subcutaneous infusion of bacterial lipopolysaccharide (LPS) in mice induced low-grade inflammation, weight gain, and hepatic insulin resistance, identifying LPS as a 'triggering factor' for diet-induced metabolic disorders. However, attributing this as an official statement of the American Diabetes Association, or framing preclinical rodent research as conclusive proof that endotoxins are the primary insult initiating insulin resistance in humans, overstates both the nature of the publication (an original animal research paper, not an ADA guideline or consensus statement) and the clinical evidence.
Approximately 40% of adults experience adult-onset acne.
"Somewhere around 40% of adults start to experience adult onset of acne, right?" (said at 0:17:50)
The claim conflates either the overall prevalence of adult acne in women or the subset of adult acne sufferers whose condition began in adulthood. Epidemiological surveys (such as Poli et al., 2001) found an overall acne prevalence of approximately 41% among adult women aged 25–40, and reported that 41% of those affected had late-onset acne (no history of adolescent acne). Consequently, adult-onset acne occurs in approximately 17% of adult women in survey data (and lower in the general adult population including men), rather than 40% of all adults.
Normal bowel transit time in a beet test is between 24 and 30 hours.
"And what you want to see is, you know, somewhere between like 24 to 30-ish hours, right? Um if you're way before that if you're like 12, 13, 14 hours, then your bowels are moving too fast. And if you're in the 40-plus hour range, your bowels are moving too slow." (said at 0:29:10)
While 24 to 30 hours is within the typical median range for whole-gut transit time in healthy adults, defining the normal reference range so narrowly—and classifying transit over 40 hours as abnormally slow—is overstated. In physiological and clinical studies using radiopaque markers, ingestible sensors, or dye tests, normal whole-gut transit time displays wide inter-individual variability, commonly ranging from 12 to 72 hours (with upper limits of normal often exceeding 70 to 120 hours depending on age, sex, diet, and defecation frequency).
A 2015 paper in Frontiers in Immunology concluded that endotoxemia is the primary cause of morbidity and mortality worldwide.
"and in fact a paper published in 2015 in Frontiers of Immunology concluded the same. They said that stress induced endotoxemia or endotoxemia on its own is the number one cause of morbidity and mortality worldwide." (said at 0:44:06)
The cited 2015 review in Frontiers in Immunology ('Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability') notes that chronic non-communicable diseases (NCDs) are the leading causes of disability and mortality worldwide. The authors present a narrative hypothesis that stress-induced intestinal permeability leading to endotoxin translocation may play a contributory or causal role in the low-grade inflammation associated with these diseases. The review does not conclude or establish that endotoxemia itself is the primary or number one cause of worldwide morbidity and mortality.
A published 30-day randomized controlled trial of a spore-based probiotic formula showed a 75% reduction in post-meal endotoxemia/LPS.
"and we published in 2017 the first time a paper has been published on a probiotic that alleviates that LPS endotoxemia. Right? So, we showed in a 30-day study, in a simple randomized controlled trial, 38 30-day study with people who had profound endotoxemia, meaning we were screening people for those that had a huge amount of LPS that leaks through. We were able to show a 75% reduction in that LPS in just that 30-day period." (said at 0:45:28)
A 2017 randomized controlled trial evaluated a 30-day supplementation of a 5-strain Bacillus spore-based probiotic in individuals identified as dietary endotoxemia 'responders' (at least a 5-fold post-meal increase in serum endotoxin). The study found a 42% reduction in postprandial endotoxin/LPS in the probiotic group (alongside a 36% increase in the placebo group), not a 75% direct reduction in LPS levels.
Microbiologist Raúl Cano isolated viable Bacillus endospores dating 25 to 40 million years old from ancient bees preserved in amber.
"His name is Raúl Cano. He did all of that work... him and his team did all the work where they found microbes in the guts of ancient fossilized honeybees that were fossilized in amber just like the mosquito in Jurassic Park, right? And he was able to isolate Bacillus endospores from them that were 50 million and as old as 250 million years old." (said at 0:50:54)
Raúl Cano and colleagues published the isolation and revival of viable Bacillus endospores (most closely related to Bacillus sphaericus) from the abdominal contents of extinct stingless bees preserved in 25- to 40-million-year-old Dominican amber (PMID: 7538699). However, the spoken claim exaggerates the age by asserting these bee-derived isolates were 'as old as 250 million years old.' Claims of viable 250-million-year-old bacteria come from separate studies of Permian salt crystals (halite), not amber-entombed bees. Furthermore, ancient DNA and spore revival claims from millions of years ago remain contentious in paleomicrobiology due to debates surrounding contamination and background radiation damage over geological timescales.
- supports: Revival and identification of bacterial spores in 25- to 40-million-year-old Dominican amb… (Science (New York, N.Y.) 1995) · cited 639x in the literature
"A bacterial spore was revived, cultured, and identified from the abdominal contents of extinct bees preserved for 25 to 40 million years in buried Dominican amber. Rigorous surface decontamination of the amber and aseptic procedures were used during the recovery of the bacterium. Several lines of evidence indicated that the isolated bacterium was of ancient origin and not an extant contaminant. The characteristic enzymatic, biochemical, and 16S ribosomal DNA profiles indicated that the ancient bacterium is most closely related to extant Bacillus sphaericus." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Bacillus DNA in fossil bees: an ancient symbiosis? (Applied and environmental microbiology 1994) · cited 95x in the literature
"We report here the isolation of DNA from abdominal tissue of four extinct stingless bees (Proplebeia dominicana) in Dominican amber, PCR amplification of a 546-bp fragment of the 16S rRNA gene from Bacillus spp., and their corresponding nucleotide sequences." (abstract, results, passage verified)
pubmedfull study (doi)
Bitter taste receptors located throughout the digestive tract account for nearly 50% of all digestive signaling in the body.
"turning on of the bitter taste receptors throughout the digestive tract accounts for almost 50% of all of the digestive signaling. Right? So, think of them as switches going through this massive machine. Turning on these switches to effectuate the digestive process requires bitter taste receptors being activated by bitter compounds" (said at 0:57:18)
While bitter taste receptors (TAS2Rs / T2Rs) are expressed throughout the gastrointestinal mucosa and play documented roles in chemoreception, hormone secretion (such as GLP-1), gastric acid secretion, motility, and metabolic regulation, there is no scientific basis or quantification showing that they account for "nearly 50% of all digestive signaling." Gastrointestinal digestion and motility are coordinated by a complex, multi-layered system dominated by the enteric nervous system (ENS), autonomic nervous system input (vagus and sympathetic nerves), peptide hormones (gastrin, CCK, secretin, motilin, ghrelin, etc.), mechanical stretch receptors, and multiple non-bitter nutrient receptors (such as sweet/umami TAS1Rs, free fatty acid GPCRs, and amino acid transporters). Claiming a specific, precise figure of 50% for bitter taste receptors dramatically overstates their contribution relative to these primary neural and hormonal signaling networks.
- context: Bitter taste receptors as sensors of gut luminal contents. (Nature reviews. Gastroenterology & hepatology 2025) · cited 42x in the literature
"These bitter taste receptors are expressed in functionally distinct types of gastrointestinal mucosal cells, including enteroendocrine cells, which, upon stimulation, increase intracellular Ca 2+ and release signalling molecules that regulate gut chemosensory processes critical for digestion and absorption of nutrients, for neutralization and expulsion of harmful substances, and for metabolic regulation." (abstract, passage verified)
pubmedfull study (doi) - context: Intestinal bitter taste receptors in health: a multifactorially regulated role from the pe… (Critical reviews in food science and nutrition 2026) · cited 1x in the literature
"Intestinal bitter taste receptors (TAS2Rs) play a crucial role in detecting bitter compounds and regulating the release of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), and gastric emptying, which influence appetite, satiety, food intake, and energy balance." (abstract, passage verified)
pubmedfull study (doi)
In a 30-day trial of a spore-based probiotic formula, participants consuming a 2,000-calorie meal experienced a 60% to 70% drop in postprandial ghrelin levels along with a significant increase in leptin.
"what we saw then, after just 30 days of not adjusting diet, lifestyle, or anything else, just taking the this the spore-based probiotic formula, what we saw was a after we gave them the 2,000 calorie meal, we saw about a 60, 70% drop in the ghrelin, the hunger hormone, and a significant increase in leptin." (said at 0:47:44)
A 30-day randomized pilot trial (McFarlin et al., 2017) evaluated a 5-strain Bacillus spore-based probiotic following a high-calorie/high-fat meal challenge in individuals with postprandial dietary endotoxemia. While the trial did find lower postprandial ghrelin concentrations in the probiotic group compared to placebo (6.8 ± 0.4 vs. 8.3 ± 1.1, P = 0.017), this represents an approximately 18% difference between groups, substantially less than the 60% to 70% reduction claimed.
Bitter receptors control upwards of half of all digestive signals in the human body.
"what a bitter is, you know, and it controls upwards of half of all your digestive signals, which is amazing." (said at 1:04:45)
Extraoral bitter taste receptors (TAS2Rs) are expressed throughout the human gastrointestinal tract on enteroendocrine, Paneth, goblet, and tuft cells, where their activation influences gut motility, mucosal defence, and the secretion of digestive and satiety hormones like GLP-1 and CCK. However, there is no scientific basis for the claim that they control 'upwards of half' of all digestive signals. Gastrointestinal physiology relies on an extensive network of diverse inputs, including the enteric and autonomic nervous systems, mechanoreceptors, and numerous specialized chemosensory receptors for macronutrients (carbohydrates, amino acids, and fats via TAS1Rs, calcium-sensing receptors, and free fatty acid receptors), along with dozens of peptide hormones and neurotransmitters.
- context: Bitter taste receptors as sensors of gut luminal contents. (Nature reviews. Gastroenterology & hepatology 2025) · cited 42x in the literature
"These bitter taste receptors are expressed in functionally distinct types of gastrointestinal mucosal cells, including enteroendocrine cells, which, upon stimulation, increase intracellular Ca 2+ and release signalling molecules that regulate gut chemosensory processes critical for digestion and absorption of nutrients, for neutralization and expulsion of harmful substances, and for metabolic regulation." (abstract, results, passage verified)
pubmedfull study (doi) - context: Intestinal bitter taste receptors in health: a multifactorially regulated role from the pe… (Critical reviews in food science and nutrition 2026) · cited 1x in the literature
"Intestinal bitter taste receptors (TAS2Rs) play a crucial role in detecting bitter compounds and regulating the release of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), and gastric emptying, which influence appetite, satiety, food intake, and energy balance." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.